A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
Condition: Bladder Cancer Interventions: Biological: Toca 511; Drug: Toca FC (extended-release formulation of flucytosine) Sponsor: Tocagen Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials